Oklahoma Medicaid

Does Oklahoma Medicaid cover Wegovy?

Quick answer · Heart Disease Risk Reduction

Oklahoma Medicaid covers Wegovy for heart disease risk reduction with prior authorization on Medicaid.

  • Medicaid: Covered with requirements. BMI of 27 or higher

Last verified June 4, 2026. Source: policy-385.html. How we verify this data →

Check your card for your exact plan →

Wegovy for Heart Disease Risk Reduction

What Oklahoma Medicaid requires, by plan type. Open this indication on its own page →

Medicaid

Covered with requirements

What you need to qualify

  • Age 45 and older
  • BMI of 27 or higher
  • A1C no higher than 6.5%
  • Established cardiovascular disease (MI, stroke, and PAD)
  • On guideline-directed medical therapy (antihypertensives, lipid-lowering agents, and antiplatelets)
  • Lab results confirming eligibility
  • Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction — initial approval

All of:

  • FDA approved indication to reduce risk of major adverse CV events
  • Member is 45 years of age or older
  • BMI >= 27 kg/m2
  • Established CVD with history of qualifying event
  • HbA1c < 6.5% (no T1DM or T2DM)
  • Not using Wegovy in combination with other semaglutide-containing products or any GLP-1 receptor agonist
  • Currently receiving GDMT for CVD (antihypertensives, lipid-lowering agents, antiplatelets) as documented in pharmacy claims history, unless contraindicated
  • Diet and exercise used in conjunction (clinical documentation required)

Plus any one of:

  • Previous myocardial infarction
  • Previous stroke
  • Symptomatic peripheral arterial disease confirmed by intermittent claudication with ankle-brachial index <0.85 at rest, OR peripheral arterial revascularization procedure, OR amputation due to atherosclerotic disease

Documentation to bring

  • Documentation of established CVD with qualifying event (previous MI, previous stroke, or symptomatic PAD confirmed by ABI <0.85, revascularization, or amputation due to atherosclerotic disease)
  • Baseline BMI >= 27 kg/m2
  • HbA1c lab result confirming < 6.5%
  • Documentation of current GDMT use (antihypertensives, lipid-lowering agents, antiplatelets) via pharmacy claims history, or documentation of contraindication
  • Clinical documentation (e.g., office notes) of diet and exercise discussion with member
  • Confirmation member will not use Wegovy in combination with other semaglutide-containing products or any GLP-1 receptor agonist

Quantity limits

  • all injection strengths — 4 pens per 28 days
  • 25mg tablets — 30 tablets per 30 days

Approval and renewal

  • Initial approval: 2 months
  • Renewal: every 12 months
  • To renew, the plan looks for Member is tolerating maintenance dosing; member has not developed T1DM or T2DM; member is continuing reduced calorie diet, increased physical activity, and GDMT for CVD where applicable. Note: BMI threshold, established CVD documentation, and age requirement are not explicitly re-verified at continuation per the document and staying on a maintenance dose of at least 1.7 mg.

Not covered when

  • Type 2 diabetes mellitus (T2DM excluded; HbA1c must be <6.5%)
  • Concurrent use with other semaglutide-containing products or any GLP-1 receptor agonist
  • Obese or overweight members without established CVD will not be approved
  • Members who cannot tolerate dose escalation after additional 8-week approval will not be approved for continuation
  • Wegovy should be discontinued if member cannot tolerate at least 1.7mg once weekly maintenance dosing
  • Type 1 diabetes

Policy note: Initial approvals are for 8-week titration periods per dose; a separate PA must be submitted for each dose. An additional 8 weeks per dose may be approved for intolerable adverse effects during escalation with documentation. Subsequent (maintenance) approvals are for 1 year. Qualifying PAD events include intermittent claudication with ABI <0.85, peripheral arterial revascularization, or amputation due to atherosclerotic disease. Both injection and tablet formulations (25mg) are addressed. Wegovy tablets (oral semaglutide) are included in the CV risk reduction criteria in this document. Last modified date on the Metabolic Disorders page is April 24, 2026.

verified June 4, 2026 · source: policy-385.html

Wegovy for Liver Disease (MASH)

What Oklahoma Medicaid requires, by plan type. Open this indication on its own page →

Medicaid

Covered with requirements

What you need to qualify

  • Age 18 and older
  • Prescribed by or in consultation with a specialist
  • Confirmed MASH diagnosis by FibroScan_VCTE, ELF_test, and liver_biopsy, fibrosis stage F2 to F3
  • Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

MASH — initial approval

All of:

  • FDA approved indication of noncirrhotic MASH
  • Member is 18 years of age or older
  • Moderate-to-advanced liver fibrosis (stage F2 or F3) confirmed by at least one accepted method
  • No chronic liver disease other than metabolic dysfunction-associated steatotic liver disease (MASLD)
  • No T1DM or T2DM
  • Metabolic comorbidities appropriately managed (T2DM, dyslipidemia, hypertension) as attested by prescriber
  • Not using Wegovy in combination with other semaglutide-containing products or any GLP-1 receptor agonist
  • Diet and exercise used in conjunction (clinical documentation required)
  • Prescribed by or in consultation with gastroenterologist or hepatologist (or advanced care practitioner supervised by gastroenterologist or hepatologist)

Plus any one of:

  • FibroScan with VCTE >= 8kPa and CAP >= 280dB/min
  • ELF biochemical test score >= 9
  • Liver biopsy showing stage F2 or F3 fibrosis with MASH

Documentation to bring

  • Results of fibrosis confirmation test (FibroScan VCTE with VCTE >=8kPa and CAP >=280dB/min, OR ELF score >=9, OR liver biopsy showing F2 or F3 fibrosis with MASH)
  • Clinical documentation (e.g., office notes) of diet and exercise discussion with member
  • Prescriber attestation that metabolic comorbidities (T2DM, dyslipidemia, hypertension) are being appropriately managed
  • Confirmation member does not have chronic liver disease other than MASLD
  • Confirmation member does not have T1DM or T2DM
  • Confirmation member will not use Wegovy in combination with other semaglutide-containing products or any GLP-1 receptor agonist
  • Documentation that prescriber is or is in consultation with a gastroenterologist or hepatologist

Quantity limits

  • all injection strengths — 4 pens per 28 days

Approval and renewal

  • Initial approval: 2 months
  • Renewal: every 12 months
  • To renew, the plan looks for Member is tolerating maintenance dosing; member has not developed T1DM or T2DM; member is continuing a reduced calorie diet and increased physical activity in conjunction with Wegovy. Note: MASH diagnosis and fibrosis staging are not explicitly re-verified at continuation per the document and staying on a maintenance dose of at least 1.7 mg.

Not covered when

  • Type 2 diabetes mellitus (T2DM excluded — member must not have T1DM or T2DM)
  • Known liver cirrhosis (stage F4)
  • Chronic liver disease other than MASLD
  • Concurrent use with other semaglutide-containing products or any GLP-1 receptor agonist
  • Obese members without MASH will not be approved
  • Members who cannot tolerate dose escalation after additional 8-week approval will not be approved for continuation
  • Wegovy should be discontinued if member cannot tolerate at least 1.7mg once weekly maintenance dosing
  • Type 1 diabetes

Policy note: Initial approvals are for 8-week titration periods per dose; a separate PA must be submitted for each dose. An additional 8 weeks per dose may be approved for intolerable adverse effects during escalation with documentation. Subsequent (maintenance) approvals are for 1 year. FibroScan threshold for MASH is >=8kPa (vs >=8.5kPa for Rezdiffra criteria). The MASH indication criteria cover Wegovy injection only (not tablets). This document also requires a prior trial of Wegovy at maintenance dosing for at least 3 months as a step-therapy prerequisite for Rezdiffra (resmetirom) — but that is a step-therapy condition for Rezdiffra, not a Wegovy PA criterion. Last modified date on the Metabolic Disorders page is April 24, 2026.

verified June 4, 2026 · source: policy-385.html

Why Wegovy requests get denied by Oklahoma Medicaid

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Wegovy and Ozempic are the same molecule with different approved uses; a request for Wegovy under a diagnosis that matches Ozempic is routinely denied.
  2. BMI not documented in the chart notes (or documented without a baseline weight and date).
  3. Prescriber isn't the specialist the plan requires.

Frequently asked questions

Does Oklahoma Medicaid cover Wegovy?
Oklahoma Medicaid covers Wegovy for heart disease risk reduction with prior authorization on Medicaid.
What BMI do you need for Wegovy under Oklahoma Medicaid?
For heart disease risk reduction on Medicaid plans, Oklahoma Medicaid requires a BMI of 27 or higher.
How long does a Wegovy approval last with Oklahoma Medicaid?
Initial approvals last 2 months, and renewals are granted in 12-month periods.
What does Oklahoma Medicaid require to renew Wegovy?
Member is tolerating maintenance dosing; member has not developed T1DM or T2DM; member is continuing reduced calorie diet, increased physical activity, and GDMT for CVD where applicable. Note: BMI threshold, established CVD documentation, and age requirement are not explicitly re-verified at continuation per the document and staying on a maintenance dose of at least 1.7 mg.
How current is this information?
This page reflects Oklahoma Medicaid's written policy as of its current version, last verified against the source document on June 4, 2026.

Other medications under Oklahoma Medicaid

Wegovy coverage under other plans

All insurance plans · All medications

This page summarizes Oklahoma Medicaid's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.